Analysis and monitoring of drug therapy in a patient with peptic ulcer complicated by infection: A case report

Table 1 Main therapeutic drugs during hospitalization

Date of administration	Name of drug	Dosage
December 23, 2022-January 3, 2023	Famotidine Injection	20 mg bid ivgtt
January 4, 2023-January 8, 2023	Lansoprazole for Injection	30 mg bid ivgtt
December 25, 2022-December 31, 2022	Ampicillin-Sulbactam	1.5 mg q8h ivgtt
December 23, 2022-January 8, 2023	Papaverine Hydrochloride Injection	60 mg qd ivgtt
December 23, 2022-January 3, 2023	Rotundine Sulfate Injection	60 mg qd im
December 23, 2022-January 8, 2023	Rotundine Sulfate Injection	1 g bid po
December 23, 2022-January 8, 2023	Kangfuxin Liquid	10 mL tid po
December 23, 2022-January 8, 2023	Zinc Acexamate Capsules	0.3 g qd po

Table 2 Blood biochemistry and infection-related indicators at admission (day 1)

Project name	Result
WBC (/μL)	5.36
TBIL (μmol/L)	14.0
AST (IU/L)	25
ALT (IU/L)	26
NEUT (%)	76.7
Na (mmoL/L)	141
K (mmoL/L)	4.6
CR (μmol/L)	75.3
PCT (μmol/L)	0.45
CRP (mg/L)	4.2

WBC: White blood cell; TBIL: Total bilirubin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; NEUT: Neutrophilic granulocyte; K: Serum potassium; Na: Serum sodium; CR: Creatinine; PCT: Procalcitonin; CRP: C-reactive protein.